newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus